000304986 001__ 304986
000304986 005__ 20251005022931.0
000304986 0247_ $$2doi$$a10.1002/ijc.70172
000304986 0247_ $$2pmid$$apmid:41002248
000304986 0247_ $$2ISSN$$a0020-7136
000304986 0247_ $$2ISSN$$a1097-0215
000304986 0247_ $$2altmetric$$aaltmetric:181719469
000304986 037__ $$aDKFZ-2025-01977
000304986 041__ $$aEnglish
000304986 082__ $$a610
000304986 1001_ $$00009-0004-4458-1609$$aKerkhoff, Maximilian$$b0
000304986 245__ $$aNew cell lines expanding the diversity of Ewing sarcoma models.
000304986 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000304986 3367_ $$2DRIVER$$aarticle
000304986 3367_ $$2DataCite$$aOutput Types/Journal article
000304986 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759230736_31252
000304986 3367_ $$2BibTeX$$aARTICLE
000304986 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304986 3367_ $$00$$2EndNote$$aJournal Article
000304986 500__ $$aepub
000304986 520__ $$aEwing sarcoma (EwS) is a highly aggressive, malignant, solid tumor of childhood, and adolescence. Most EwS develop in bone, while it originates from connective, adipose, or muscle tissue less frequently. We report the establishment of new human EwS cell lines, all of which carry a t(11;22)(q24;q12) translocation generating the oncogenic transcription factor EWSR1::FLI1. Sequencing of the chimeric mRNAs indicated genomic DNA breakpoints localized in intron 8 of the EWSR1 gene and three different introns of the translocation partner gene FLI1. While three EwS cell lines carry the EWSR1::FLI1 fusions of ex7/ex6 (type I) or ex7/ex5 (type II), the EWSR1::FLI1 fusion variant ex7/ex7 (type IV) is described for the first time in a continuous EwS model. The cell lines presented genomic, epigenomic, and transcriptomic stability over a period of 6 months, though some variations in the chromosomal aberrations were observed in one cell line. TP53, STAG2, and CDKN2A/B mutations were the most frequent and most relevant mutations in our cell line panel. The TP53 mutational status seemed to have the biggest impact on drug sensitivity profiles. The new EwS models presented here may help to identify small molecule inhibitors that act directly on EWSR1::FLI1 fusion proteins or uncover other genetic vulnerabilities of the altered epigenome and transcriptome in EwS, which would contribute to a better understanding of Ewing sarcoma tumorigenesis.
000304986 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000304986 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304986 650_7 $$2Other$$a(epi‐)genomics
000304986 650_7 $$2Other$$aEwing sarcoma
000304986 650_7 $$2Other$$acell line establishment
000304986 650_7 $$2Other$$adrug screen
000304986 650_7 $$2Other$$atranscriptomics
000304986 7001_ $$0P:(DE-HGF)0$$aSchaefer, Christiane$$b1
000304986 7001_ $$aDirks, Wilhelm G$$b2
000304986 7001_ $$0P:(DE-HGF)0$$aKrzeciesa, Dawid$$b3
000304986 7001_ $$0P:(DE-HGF)0$$aBretschneider, Maximilian$$b4
000304986 7001_ $$0P:(DE-HGF)0$$aPlaumann, Pauline R$$b5
000304986 7001_ $$0P:(DE-HGF)0$$aGuder, Wiebke K$$b6
000304986 7001_ $$0P:(DE-HGF)0$$aStreitbürger, Arne$$b7
000304986 7001_ $$0P:(DE-He78)ea170691ed65b95f10820c4c61d6e2cd$$aHerter, Sonja$$b8$$udkfz
000304986 7001_ $$0P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aPeterziel, Heike$$b9$$udkfz
000304986 7001_ $$0P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aOehme, Ina$$b10$$udkfz
000304986 7001_ $$0P:(DE-He78)ec64d75fe6aad968b3981bc1c1529f72$$aZahnow, Felina$$b11$$udkfz
000304986 7001_ $$0P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aGrünewald, Thomas G P$$b12$$udkfz
000304986 7001_ $$00000-0002-5435-7860$$aDirksen, Uta$$b13
000304986 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.70172$$gp. ijc.70172$$pnn$$tInternational journal of cancer$$vnn$$x0020-7136$$y2025
000304986 909CO $$ooai:inrepo02.dkfz.de:304986$$pVDB
000304986 9101_ $$0I:(DE-588b)2036810-0$$60009-0004-4458-1609$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea170691ed65b95f10820c4c61d6e2cd$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ec64d75fe6aad968b3981bc1c1529f72$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000304986 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-5435-7860$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000304986 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000304986 9141_ $$y2025
000304986 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000304986 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000304986 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000304986 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000304986 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000304986 9201_ $$0I:(DE-He78)B410-20160331$$kB410$$lTranslationale Pädiatrische Sarkomforschung$$x1
000304986 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000304986 980__ $$ajournal
000304986 980__ $$aVDB
000304986 980__ $$aI:(DE-He78)ED01-20160331
000304986 980__ $$aI:(DE-He78)B410-20160331
000304986 980__ $$aI:(DE-He78)HD01-20160331
000304986 980__ $$aUNRESTRICTED